Key Events This Week
15 Sep: Stock opened at Rs.1,934.30, down 1.79% amid broad market weakness
16 Sep: Modest recovery with 0.80% gain to Rs.1,949.85
17 Sep: New 52-week high at Rs.2,006.90 and all-time high close at Rs.2,000.05
18 Sep: New 52-week high of Rs.2,039.15 and all-time high close at Rs.2,022.30

Broad-Based Technical Strength Lifts Ipca Laboratories Ltd to 52-Week High of Rs 2039.15
2026-09-18 15:36:05With a decisive break above Rs 2,000, Ipca Laboratories Ltd has surged to a new 52-week high of Rs 2,039.15 on 18 Sep 2026, marking a significant milestone in its price momentum. This advance comes amid a backdrop of strong technical signals and sustained upward price action over recent sessions.
Read full news article
Broad-Based Technical Strength Lifts Ipca Laboratories Ltd to 52-Week High of Rs 2006.9
2026-09-17 10:14:46Surging past Rs 2,000 for the first time on 17 Sep 2026, Ipca Laboratories Ltd has marked a significant milestone by hitting a fresh 52-week high of Rs 2,006.9. This achievement caps a remarkable 52.47% rally over the past year, substantially outperforming the Sensex, which has declined by 9.82% during the same period.
Read full news article
Ipca Laboratories Ltd Hits All-Time High of Rs 2,000 as Momentum Builds Across Timeframes
2026-09-17 10:06:47Extending its recent gains, Ipca Laboratories Ltd touched a fresh all-time high of Rs 2,000.05 on 17 Sep 2026, marking a significant milestone for the mid-cap pharmaceutical player amid broad-based outperformance against the Sensex and sector peers.
Read full news article
Ipca Laboratories Ltd is Rated Buy by MarketsMOJO
2026-09-10 10:11:12Ipca Laboratories Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 18 August 2026. While the rating adjustment occurred on that date, the analysis and financial metrics presented here reflect the stock's current position as of 10 September 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Read full news article









